Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O…#chrs #surfaceoncologyinc #surface #dennylanfear #cimerliand #novartisag #gskplc #pipeline #udenyca #cimerli
Source: Reuters: Health - Category: Consumer Health News Source Type: news